January 17, 2017 / 16:49 IST
HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects
Glenmark Pharma to report net profit at Rs 310 crore up 37.3% quarter-on-quarter.
Net Sales are expected to increase by 0.9 percent Q-o-Q (down 27.1 percent Y-o-Y) to Rs 2190 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 26.7 percent Q-o-Q (up 49.2 percent Y-o-Y) to Rs 500 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!